Suzuki GB PLC is very pleased to announce that Young Driver, the UK’s foremost under-17s driver-training company, has just ...

Suzuki’s automatic Swift would be an ideal first car for the growing number of manual-avoiding learner drivers ...

Taylor Swift was seen leaving for Los Angeles on Wednesday after spending the beginning of the week with her Super Bowl-bound boyfriend, Kansas City Chiefs tight end Travis Kelce. The departure ...

LISBON, Jan 31 (Reuters) - U.S. private equity firm Lone Star has told the Portuguese government that it is likely to sell a 25-30% stake in Novo Banco via an initial public offering, rather than ...

(Image Credits: Pixabay) The United States Food and Drug Administration (USFDA) has approved Novo Nordisk’s Ozempic for reducing the risk of kidney failure and disease progression. According to ...

Suzuki Access 125 is a 124cc scooter with price starting from Rs. 81,700. It is available in 5 colours and 3 variants. Access 125 is a fuel efficient bike with mileage of 45 kmpl. The bike gets ...

Suzuki's popular hatchback continues to deliver as a nimble and charming city car with impressive cost-of-ownership credentials, but troubling safety performance raises questions about its ...

Your browser does not support the audio element. The Suzuki Access 125 launched at the Auto Expo 2025 may come across as an updated model, but it is actually a new ...

Maruti first grabbed highlights with the launch of the Maruti Suzuki Grand Vitara. But the other reason for its fame at the expo is the range of custom cars up for showcase. The custom Swift ...

At Auto Expo 2025, Maruti Suzuki, the nation's largest carmaker, revealed its first-ever EV in the form of the e Vitara. The electric Maruti Suzuki e Vitara SUV is the production-spec version of ...

The second Suzuki concept is called the Swift Champions, based on the new-generation model that debuted in Australia last year. Building on the hatchback’s new design, the Champions kit adds a front ...

It is the largest study ever of the drug category—which includes Novo Nordisk’s GLP-1 treatments Ozempic and Wegovy and Eli Lilly’s dual-action GLP-1/GIP agonists Mounjaro and Zepbound.